[go: up one dir, main page]

AU2002221491A1 - A composition of sodium channel blocking compound - Google Patents

A composition of sodium channel blocking compound

Info

Publication number
AU2002221491A1
AU2002221491A1 AU2002221491A AU2149102A AU2002221491A1 AU 2002221491 A1 AU2002221491 A1 AU 2002221491A1 AU 2002221491 A AU2002221491 A AU 2002221491A AU 2149102 A AU2149102 A AU 2149102A AU 2002221491 A1 AU2002221491 A1 AU 2002221491A1
Authority
AU
Australia
Prior art keywords
sodium channel
composition
blocking compound
channel blocking
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221491A
Inventor
Yuhong Kang
Frank Haykong Shum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanning Maple Leaf Pharmaceutical Co Ltd
Original Assignee
Nanning Maple Leaf Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanning Maple Leaf Pharmaceutical Co Ltd filed Critical Nanning Maple Leaf Pharmaceutical Co Ltd
Publication of AU2002221491A1 publication Critical patent/AU2002221491A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The composition of the present invention comprises a sodium channel blocking compound which is capable of specifically binding to a site, either on an SS region or an SS2 region, on an extracellular region of a sodium channel alpha subunit, and a pharmaceutically acceptable carrier.
AU2002221491A 2000-11-22 2001-11-19 A composition of sodium channel blocking compound Abandoned AU2002221491A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN00132672 2000-11-22
CNB001326724A CN1236773C (en) 2000-11-22 2000-11-22 Preparation for analgesia and anesthesia or curing drug dependence
PCT/CN2001/001566 WO2002041915A1 (en) 2000-11-22 2001-11-19 A composition of sodium channel blocking compound

Publications (1)

Publication Number Publication Date
AU2002221491A1 true AU2002221491A1 (en) 2002-06-03

Family

ID=4595311

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221491A Abandoned AU2002221491A1 (en) 2000-11-22 2001-11-19 A composition of sodium channel blocking compound

Country Status (8)

Country Link
US (1) US6559154B2 (en)
EP (2) EP1335747B1 (en)
JP (1) JP2004513186A (en)
CN (1) CN1236773C (en)
AT (1) ATE385799T1 (en)
AU (1) AU2002221491A1 (en)
DE (1) DE60132798T2 (en)
WO (1) WO2002041915A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284536C (en) * 2000-09-18 2006-11-15 威克斯医药有限公司 Use of tetrodotoxin or saxitoxin and analogs thereof in the preparation of analgesics for systemic analgesia
CN1269482C (en) * 2001-05-18 2006-08-16 威克斯医药有限公司 Use of sodium ion channel blocker and opioid analgesic in the preparation of medicines for synergistic analgesia in mammals
EA006739B1 (en) 2001-11-15 2006-04-28 Майкроу Элджи Корпорейшн Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
CN1568999A (en) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 Stable freeze dried formulation of spheroidine for medical use
BRPI0510760A (en) * 2004-05-07 2007-11-20 Phytotox Ltd method for administering to a patient a composition, topical composition, and patch
CA2606530C (en) * 2004-05-07 2014-01-07 Phytotox Limited Phycotoxins and uses thereof
EP1799219A1 (en) * 2004-09-21 2007-06-27 Laboratorios del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
US20100075992A1 (en) * 2004-09-22 2010-03-25 Laboratorios Del Dr. Esteve S.A. Tetrodotoxin and its derivatives for the treament of peripheral-nervously derived neuropathi pain
WO2006101629A2 (en) * 2005-02-17 2006-09-28 Vertex Pharmaceuticals Incorporated SODIUM CHANNEL PROTEIN TYPE III α-SUBUNIT SPLICE VARIANT
EP1928452A4 (en) * 2005-08-25 2010-09-01 Wex Medical Ltd Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
WO2007025213A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the management of musculoskeletal pain
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
EP2012774A1 (en) 2006-03-27 2009-01-14 Wex Pharmaceuticals, Inc Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US8658699B2 (en) 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
CN101352422B (en) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 Tetrodotoxin lyophilized powder formulation for injection and preparation method thereof
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
JP6313420B2 (en) 2013-03-15 2018-04-18 ザ チルドレンズ メディカル センター コーポレイション Neosaxitoxin combination formulation for sustained local anesthesia
JP2024518821A (en) * 2021-04-23 2024-05-07 ウェクス ファーマシューティカルズ インコーポレイテッド Tetrodotoxin liquid preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US3898339A (en) * 1973-08-14 1975-08-05 Astra Pharma Prod Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
DE69529156T2 (en) * 1994-03-17 2003-09-25 Nanning Maple Leaf Pharmaceutical Co., Ltd. USE OF AMINO-HYDROGENATED CHINAZOLINE COMPOUNDS AND THEIR DERIVATIVES FOR BODYING IN DRUG ADDICTION
CN1081034C (en) * 1997-03-07 2002-03-20 潘心富 Medicine of diguanidino-prine-hydride compounds for giving up drug-taking
WO1998043619A2 (en) * 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
AU7389098A (en) * 1997-05-16 1998-12-08 Brigham And Women's Hospital Local anesthetic formulations
CN1284536C (en) 2000-09-18 2006-11-15 威克斯医药有限公司 Use of tetrodotoxin or saxitoxin and analogs thereof in the preparation of analgesics for systemic analgesia
CN1240702C (en) 2000-09-18 2006-02-08 威克斯医药有限公司 Method for extracting tetradosin with high yield
CN1203857C (en) * 2000-09-18 2005-06-01 威克斯医药有限公司 A New Approach to Local Anesthesia and Analgesia

Also Published As

Publication number Publication date
EP1335747B1 (en) 2008-02-13
US20020119987A1 (en) 2002-08-29
JP2004513186A (en) 2004-04-30
CN1353990A (en) 2002-06-19
US6559154B2 (en) 2003-05-06
ATE385799T1 (en) 2008-03-15
EP1930027A2 (en) 2008-06-11
DE60132798D1 (en) 2008-03-27
WO2002041915A1 (en) 2002-05-30
EP1335747A1 (en) 2003-08-20
DE60132798T2 (en) 2009-02-12
EP1335747A4 (en) 2005-10-12
CN1236773C (en) 2006-01-18
EP1930027A3 (en) 2008-06-18

Similar Documents

Publication Publication Date Title
AU2002221491A1 (en) A composition of sodium channel blocking compound
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
MXPA03005904A (en) Modified rubber-based adhesives.
DE69802615D1 (en) Triaromatic compounds, compositions containing them and their uses
YU82403A (en) Spiropyrazole compounds
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
AU2001266575A1 (en) Chemical compounds
AU2002235764A1 (en) Transdermal system containing a novel high potency progestagen
AU2001286540A1 (en) Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
MXPA03009602A (en) Nociceptin analogs.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU2002213419A1 (en) Condensed pyridoindole derivatives
WO2002011737A3 (en) Anti-inflammatory medicament
HK1043058A1 (en) Isophosphoramide mustard analogs and use thereof
AU6339000A (en) Serotonergic benzothiophenes
AU2001263235A1 (en) Optical channel shared protection ring
AU2001288332A1 (en) Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
AU2003274565A1 (en) Composition for the treatment of nasopharyngeal carcinoma and use thereof
AU2002230579A1 (en) Calcilytic compounds
AU2001273888A1 (en) New sodium channel (rnav1.5a) and use thereof
AU2001232089A1 (en) Compound, composition and use
AU2001232080A1 (en) Compound, compositions and use
FI990785A7 (en) Telephone communication system
BR8002856U (en) Television watch
AU2001287673A1 (en) Novel trioxepan compounds